PROK ProKidney Corp.
Stock Price & Overview

$0.910.16 (+21.49%)4:00 PM 04/23/25
NASDAQ | $USD | Post-Market: $0.88 -0.03 (-3.72%) 7:01 PM

PROK Stock Price

EPS
PE
Div Rate
Yield
Short Interest
Market Cap
Volume
Prev. Close
Expand For Key Data »

Quant Ranking

PROK Analysis

PROK News

See All News »

Latest Headlines

Ratings Summary

People Also Follow

Similar to PROK

ETFs Holding PROK

PROK Company Profile

ProKidney Corp. logo
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Sector
Health Care
Industry
Biotechnology
Employees
204
Founded
2015
Address
  • 2000 Frontis Plaza Blvd.
  • Suite 250
  • Winston-Salem, NC, 27103
  • United States
Phone Number
336 999 7028
Website
prokidney.com
Hide

PROK Revenue

More On Revenue »

PROK Earnings Per Share

More On Earnings »

Earnings Estimates

Earnings Revisions

Valuation

Profitability

Momentum

Capital Structure

Dividends

PROK does not currently pay a dividend.

PROK Ownership

PROK Peers

Risk

Technicals

PROK Transcripts

PROK SEC Filings

See All SEC Filings »

Press Releases

See All Press Releases »

PROK Income Statement

PROK Balance Sheet

PROK Cash Flow Statement

PROK Long Term Solvency

Discover More

You may be interested in:

ProKidney Corp. (PROK) Frequently Asked Questions